MA38974A1 - Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate - Google Patents
Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olateInfo
- Publication number
- MA38974A1 MA38974A1 MA38974A MA38974A MA38974A1 MA 38974 A1 MA38974 A1 MA 38974A1 MA 38974 A MA38974 A MA 38974A MA 38974 A MA38974 A MA 38974A MA 38974 A1 MA38974 A1 MA 38974A1
- Authority
- MA
- Morocco
- Prior art keywords
- dosage forms
- morpholin
- triazol
- pyrazol
- pyrimidin
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- VYRQLKYGGSWDNH-UHFFFAOYSA-M sodium;2-(6-morpholin-4-ylpyrimidin-4-yl)-4-(triazol-1-yl)pyrazol-3-olate Chemical compound [Na+].[O-]C1=C(N2N=NC=C2)C=NN1C(N=CN=1)=CC=1N1CCOCC1 VYRQLKYGGSWDNH-UHFFFAOYSA-M 0.000 title 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical compound OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne des formes galéniques pharmaceutiques pour administration orale contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate (principe actif (i). Selon l'invention, le principe actif (i) est libéré. L'invention concerne également un procédé de production desdites formes galéniques, leur utilisation comme médicament, ainsi que leur utilisation pour la prophylaxie, la prophylaxie secondaire ou le traitement de maladies, en particulier les maladies cardiovasculaires, l'insuffisance cardiaque, l'anémie, les maladies rénales chroniques et l'insuffisance rénale.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13189145 | 2013-10-17 | ||
| PCT/EP2014/071855 WO2015055564A1 (fr) | 2013-10-17 | 2014-10-13 | Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38974A1 true MA38974A1 (fr) | 2017-05-31 |
| MA38974B2 MA38974B2 (fr) | 2020-11-30 |
Family
ID=49356354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38974A MA38974B2 (fr) | 2013-10-17 | 2014-10-13 | Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9827198B2 (fr) |
| EP (1) | EP3057580B1 (fr) |
| JP (1) | JP6525979B2 (fr) |
| KR (1) | KR102330953B1 (fr) |
| CN (1) | CN105636580B (fr) |
| AP (1) | AP2016009135A0 (fr) |
| AR (1) | AR098064A1 (fr) |
| AU (1) | AU2014336389B2 (fr) |
| BR (1) | BR112016007588A2 (fr) |
| CA (1) | CA2927437C (fr) |
| CL (1) | CL2016000857A1 (fr) |
| CU (1) | CU24515B1 (fr) |
| DK (1) | DK3057580T3 (fr) |
| DO (1) | DOP2016000078A (fr) |
| EA (1) | EA032932B1 (fr) |
| ES (1) | ES2868228T3 (fr) |
| GT (1) | GT201600072A (fr) |
| HR (1) | HRP20210691T1 (fr) |
| HU (1) | HUE054107T2 (fr) |
| IL (1) | IL244933B (fr) |
| JO (1) | JO3645B1 (fr) |
| LT (1) | LT3057580T (fr) |
| MA (1) | MA38974B2 (fr) |
| MX (1) | MX2016004628A (fr) |
| MY (1) | MY190202A (fr) |
| NI (1) | NI201600054A (fr) |
| PE (1) | PE20160669A1 (fr) |
| PH (1) | PH12016500716A1 (fr) |
| SA (1) | SA516370940B1 (fr) |
| SI (1) | SI3057580T1 (fr) |
| TN (1) | TN2016000135A1 (fr) |
| TW (1) | TWI746418B (fr) |
| UA (1) | UA119855C2 (fr) |
| UY (1) | UY35784A (fr) |
| WO (1) | WO2015055564A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210346392A1 (en) * | 2018-08-31 | 2021-11-11 | Astellas Pharma Inc. | Pharmaceutical composition for oral administration |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| WO2008120548A2 (fr) * | 2007-03-13 | 2008-10-09 | Dainippon Sumitomo Pharma Co., Ltd. | Comprimé à désintégration orale |
| DE102010044131A1 (de) * | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
-
2014
- 2014-10-13 US US15/029,215 patent/US9827198B2/en active Active
- 2014-10-13 HU HUE14783642A patent/HUE054107T2/hu unknown
- 2014-10-13 HR HRP20210691TT patent/HRP20210691T1/hr unknown
- 2014-10-13 LT LTEP14783642.3T patent/LT3057580T/lt unknown
- 2014-10-13 WO PCT/EP2014/071855 patent/WO2015055564A1/fr not_active Ceased
- 2014-10-13 AU AU2014336389A patent/AU2014336389B2/en not_active Ceased
- 2014-10-13 AP AP2016009135A patent/AP2016009135A0/en unknown
- 2014-10-13 KR KR1020167009621A patent/KR102330953B1/ko not_active Expired - Fee Related
- 2014-10-13 MA MA38974A patent/MA38974B2/fr unknown
- 2014-10-13 MX MX2016004628A patent/MX2016004628A/es unknown
- 2014-10-13 CA CA2927437A patent/CA2927437C/fr active Active
- 2014-10-13 EP EP14783642.3A patent/EP3057580B1/fr active Active
- 2014-10-13 EA EA201690788A patent/EA032932B1/ru not_active IP Right Cessation
- 2014-10-13 PE PE2016000498A patent/PE20160669A1/es unknown
- 2014-10-13 CN CN201480056547.1A patent/CN105636580B/zh not_active Expired - Fee Related
- 2014-10-13 BR BR112016007588A patent/BR112016007588A2/pt not_active Application Discontinuation
- 2014-10-13 CU CU2016000048A patent/CU24515B1/es unknown
- 2014-10-13 UA UAA201605150A patent/UA119855C2/uk unknown
- 2014-10-13 TN TN2016000135A patent/TN2016000135A1/en unknown
- 2014-10-13 MY MYPI2016701355A patent/MY190202A/en unknown
- 2014-10-13 ES ES14783642T patent/ES2868228T3/es active Active
- 2014-10-13 JP JP2016523207A patent/JP6525979B2/ja active Active
- 2014-10-13 DK DK14783642.3T patent/DK3057580T3/da active
- 2014-10-13 SI SI201431801T patent/SI3057580T1/sl unknown
- 2014-10-15 UY UY0001035784A patent/UY35784A/es not_active Application Discontinuation
- 2014-10-15 TW TW103135607A patent/TWI746418B/zh not_active IP Right Cessation
- 2014-10-16 JO JOP/2014/0295A patent/JO3645B1/ar active
- 2014-10-17 AR ARP140103868A patent/AR098064A1/es unknown
-
2016
- 2016-04-04 IL IL244933A patent/IL244933B/en active IP Right Grant
- 2016-04-08 DO DO2016000078A patent/DOP2016000078A/es unknown
- 2016-04-12 CL CL2016000857A patent/CL2016000857A1/es unknown
- 2016-04-14 NI NI201600054A patent/NI201600054A/es unknown
- 2016-04-14 GT GT201600072A patent/GT201600072A/es unknown
- 2016-04-14 SA SA516370940A patent/SA516370940B1/ar unknown
- 2016-04-15 PH PH12016500716A patent/PH12016500716A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37405A1 (fr) | Composés hétérocyclyle | |
| MA30914B1 (fr) | Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques. | |
| MA35348B1 (fr) | 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk | |
| MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
| MA38076A1 (fr) | Dérivés d'oxazolidin-2-one-pyrimidine | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| NZ778223A (en) | Modified release tablet formulations containing phosphodiesterase inhibitors | |
| MA37721B1 (fr) | Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide | |
| MA34671B1 (fr) | Sel de sodium de 1h-pyrazol-5-olate substitué | |
| MA38925A1 (fr) | Dérivés de phénylalanine substitués | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MA38215A1 (fr) | Composition pharmaceutique ophtalmologique topique contenant regorafenib | |
| MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque | |
| MA38974A1 (fr) | Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| EP2862573A4 (fr) | Composition pour le traitement ou la prévention de maladies causées par une perméabilité vasculaire, contenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif | |
| FI3137094T3 (fi) | Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen | |
| MA38599A1 (fr) | Nouveaux dérivés pyrazolopyrrolidine et leur utilisation dans le traitement de maladies | |
| NZ740690A (en) | Treatment of alopecia areata | |
| MA38473B1 (fr) | (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c | |
| FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives | |
| MA39446A1 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses |